Patients were excluded if they (a) were currently receiving psychotherapy or antidepressant drugs (unless they had been taking the same dose for at least three months without improvement); (b) were unwilling to accept randomisation or were unavailable for follow up; (c) met criteria for severe depression (melancholia) or had a history of bipolar affective disorder, schizophrenia, or substance misuse (as defined in the Diagnostic and Statistical Manual of Mental Disorders, third edition, revised (DSM - III - R) 18); or (d) were at significant risk of suicide or in need of
urgent psychiatric treatment.
A young girl from the Nauru detention centre must be brought to Australia for
urgent psychiatric treatment, a court finds, warning she could take her own life without intervention.
Not exact matches
PTSD is a severe
psychiatric illness characterised by four core symptom clusters: re-experiencing, avoidance, negative cognition and mood and hyperarousal.1 With an estimated lifetime prevalence in community samples of up to 8 %, PTSD results in a great deal of personal suffering and escalating social and economic costs.2 Unfortunately, current evidence - based
treatments for PTSD leave a high percentage with a significant symptom burden, highlighting the
urgent need for novel
treatments.